Helix Biopharma Corp. will collaborate with ProMab Biotechnologies Inc. to develop cell-based therapies.
Under a nonbinding letter of intent, the companies will complete a due diligence and establish a collaboration to develop chimeric antigen receptor T cell therapy for hematological malignancies and solid tumors.